Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Grass MATA MPL · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Grass MATA MPL | BIOLOGICAL | - |
Inclusion Criteria: * Positive skin prick test to grass and rye pollen allergen extract * Positive skin prick test to positive histamine control * Negative skin prick test to negative control * Specific IgE for grass and rye as documented by a RAST or equivalent test * Females of childbearing poten...
Grass MATA MPL is an investigational monoclonal antibody being developed for Type I Hypersensitivity, a condition involving allergic reactions. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied for its potential to address this allergic condition.
Grass MATA MPL is being developed by cbdMD, Inc., a company traded on the stock exchange under the ticker symbol YCBD. The company is conducting clinical research on this investigational monoclonal antibody for Type I Hypersensitivity.
Grass MATA MPL is in Phase 1 clinical development. It is an investigational drug and has not received regulatory approval. The Phase 1 trial has been completed, and the drug remains in early-stage clinical development for Type I Hypersensitivity.
Grass MATA MPL has one completed Phase 1 clinical trial registered as NCT00104390, titled 'Assessment of Residual Allergenicity of Grass/Rye Pollen Allergoid Using Skin Prick Testing.' The trial enrolled 14 participants in the United States and was not randomized or double-blinded.
Grass MATA MPL is not FDA approved. It is an investigational monoclonal antibody currently in Phase 1 clinical development for Type I Hypersensitivity. The drug has completed one early-stage clinical trial but has not yet received regulatory approval for any use.